{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:54:48Z","timestamp":1793325288479,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Invasive candidiasis and candidemia remain a significant public health concern. The European Confederation of Medical Mycology (ECMM) conducted three pan-European multicentre studies from 1997 to 2022 to investigate various aspects of invasive <jats:italic>Candida<\/jats:italic> infections. These studies revealed shifting trends in <jats:italic>Candida<\/jats:italic> species distribution, with an increase of non-<jats:italic>albicans Candida<\/jats:italic> species as causative pathogens, increasing rates of antifungal resistance, and persistently high mortality rates. Despite advancements in antifungal treatment, the persistently high mortality rate and increasing drug resistance, as well as limited drug access in low-income countries, underscore the need for continued research and development in the treatment of <jats:italic>Candida<\/jats:italic> infections. This review aims to summarize the findings of the three completed ECMM <jats:italic>Candida<\/jats:italic> studies and emphasize the importance of continued research efforts. Additionally, it introduces the upcoming ECMM <jats:italic>Candida<\/jats:italic> IV study, which will focus on assessing candidemia caused by non-<jats:italic>albicans Candida<\/jats:italic> species, including <jats:italic>Candida auris<\/jats:italic>, investigating antifungal resistance and tolerance, and evaluating novel treatment modalities on a global scale.<\/jats:p>","DOI":"10.1007\/s11046-024-00871-0","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T15:02:38Z","timestamp":1722524558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Insights from Three Pan-European Multicentre Studies on Invasive Candida Infections and Outlook to ECMM Candida IV"],"prefix":"10.1007","volume":"189","author":[{"given":"Stella","family":"Wolfgruber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sedik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Klingspor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Tortorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A. R.","family":"Gow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Gangneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques F.","family":"Meis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Lass-Fl\u00f6rl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevtap","family":"Arikan-Akdagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-2824","authenticated-orcid":false,"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"issue":"1","key":"871_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3201\/eid2301.161198","volume":"23","author":"S Strollo","year":"2016","unstructured":"Strollo S, et al. Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002\u20132012(1). Emerg Infect Dis. 2016;23(1):7\u201313.","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"871_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/jof9040430","volume":"9","author":"CA Alvarez-Moreno","year":"2023","unstructured":"Alvarez-Moreno CA, et al. The mortality attributable to Candidemia in C. auris is higher than that in other Candida species: myth or reality? J Fungi (Basel). 2023;9(4):430.","journal-title":"J Fungi (Basel)"},{"key":"871_CR3","doi-asserted-by":"publisher","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","volume":"4","author":"PG Pappas","year":"2018","unstructured":"Pappas PG, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"871_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/myc.13449","volume":"65","author":"M Egger","year":"2022","unstructured":"Egger M, et al. Let\u2019s talk about sex characteristics-As a risk factor for invasive fungal diseases. Mycoses. 2022;65(6):599\u2013612.","journal-title":"Mycoses"},{"issue":"9","key":"871_CR5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/myc.13332","volume":"64","author":"B Kayaaslan","year":"2021","unstructured":"Kayaaslan B, et al. Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients. Mycoses. 2021;64(9):1083\u201391.","journal-title":"Mycoses"},{"issue":"4","key":"871_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","volume":"3","author":"F Bongomin","year":"2017","unstructured":"Bongomin F, et al. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel). 2017;3(4):57.","journal-title":"J Fungi (Basel)"},{"key":"871_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1473-3099(24)00102-6","volume":"24","author":"DW Denning","year":"2024","unstructured":"Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024;24:268.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"871_CR8","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3390\/antibiotics11060718","volume":"11","author":"N Barantsevich","year":"2022","unstructured":"Barantsevich N, Barantsevich E. Diagnosis and treatment of invasive candidiasis. Antibiotics (Basel). 2022;11(6):718.","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"871_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","volume":"23","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care. 2019;23(1):219.","journal-title":"Crit Care"},{"key":"871_CR10","doi-asserted-by":"publisher","first-page":"e0087323","DOI":"10.1128\/jcm.00873-23","volume":"25","author":"S de Hoog","year":"2023","unstructured":"de Hoog S, et al. A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC. J Clin Microbiol. 2023;25:e0087323.","journal-title":"J Clin Microbiol"},{"key":"871_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/204237","volume":"2013","author":"C Spampinato","year":"2013","unstructured":"Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed Res Int. 2013;2013: 204237.","journal-title":"Biomed Res Int"},{"key":"871_CR12","first-page":"56","volume":"879","author":"D Seidel","year":"2024","unstructured":"Seidel D, et al. Impact of climate change and natural disasters on fungal infections. Lancet Microbe. 2024;879:56\u20138.","journal-title":"Lancet Microbe"},{"issue":"1","key":"871_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1348-0421.2008.00083.x","volume":"53","author":"K Satoh","year":"2009","unstructured":"Satoh K, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41\u20134.","journal-title":"Microbiol Immunol"},{"issue":"4","key":"871_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1128\/mBio.01397-19","volume":"10","author":"A Casadevall","year":"2019","unstructured":"Casadevall A, Kontoyiannis DP, Robert V. On the emergence of Candida auris: climate change, azoles, swamps, and birds. MBio. 2019;10(4):785.","journal-title":"MBio"},{"issue":"4","key":"871_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41579-023-00861-x","volume":"21","author":"MC Fisher","year":"2023","unstructured":"Fisher MC, Denning DW. The WHO fungal priority pathogens list as a game-changer. Nat Rev Microbiol. 2023;21(4):211\u20132.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"871_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.7326\/M22-3469","volume":"176","author":"M Lyman","year":"2023","unstructured":"Lyman M, et al. Worsening spread of Candida auris in the United States, 2019 to 2021. Ann Intern Med. 2023;176(4):489\u201395.","journal-title":"Ann Intern Med"},{"key":"871_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1146\/annurev-micro-032521-015858","volume":"77","author":"A Chowdhary","year":"2023","unstructured":"Chowdhary A, Jain K, Chauhan N. Candida auris genetics and emergence. Annu Rev Microbiol. 2023;77:583\u2013602.","journal-title":"Annu Rev Microbiol"},{"issue":"1","key":"871_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-024-00503-3","volume":"10","author":"C Lass-Fl\u00f6rl","year":"2024","unstructured":"Lass-Fl\u00f6rl C, et al. Invasive candidiasis. Nat Rev Dis Primers. 2024;10(1):20.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"871_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10096-004-1103-y","volume":"23","author":"AM Tortorano","year":"2004","unstructured":"Tortorano AM, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004;23(4):317\u201322.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"871_CR20","doi-asserted-by":"publisher","first-page":"87.e1","DOI":"10.1016\/j.cmi.2014.08.011","volume":"21","author":"L Klingspor","year":"2015","unstructured":"Klingspor L, et al. Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006\u20132008). Clin Microbiol Infect. 2015;21(1):87.e1-87.e10.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"871_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1473-3099(22)00872-6","volume":"23","author":"M Hoenigl","year":"2023","unstructured":"Hoenigl M, et al. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. Lancet Infect Dis. 2023;23(6):751\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"871_CR22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/myc.12746","volume":"61","author":"SC Mellinghoff","year":"2018","unstructured":"Mellinghoff SC, et al. EQUAL Candida Score: An ECMM score derived from current guidelines to measure QUAlity of Clinical Candidaemia Management. Mycoses. 2018;61(5):326\u201330.","journal-title":"Mycoses"},{"issue":"3","key":"871_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/jof8030238","volume":"8","author":"A El Zakhem","year":"2022","unstructured":"El Zakhem A, et al. The utility of EQUAL candida score in predicting mortality in patients with candidemia. J Fungi (Basel). 2022;8(3):238.","journal-title":"J Fungi (Basel)"},{"issue":"4","key":"871_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/myc.13429","volume":"65","author":"T Leepattarakit","year":"2022","unstructured":"Leepattarakit T, et al. EQUAL Candida score, an effective tool for predicting the outcomes of Candida tropicalis candidaemia: a retrospective cohort study. Mycoses. 2022;65(4):473\u201380.","journal-title":"Mycoses"},{"issue":"12","key":"871_CR25","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"871_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/1469-0691.12038","volume":"18","author":"M Cuenca-Estrella","year":"2012","unstructured":"Cuenca-Estrella M, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18(Suppl 7):9\u201318.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"871_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000612","volume":"5","author":"J Salmanton-Garc\u00eda","year":"2021","unstructured":"Salmanton-Garc\u00eda J, et al. EPICOVIDEHA: a ready to use platform for epidemiological studies in hematological patients with COVID-19. Hemasphere. 2021;5(7): e612.","journal-title":"Hemasphere"},{"issue":"8","key":"871_CR28","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/myc.12631","volume":"60","author":"D Seidel","year":"2017","unstructured":"Seidel D, et al. FungiScope(\u2122)-global emerging fungal infection registry. Mycoses. 2017;60(8):508\u201316.","journal-title":"Mycoses"},{"issue":"11","key":"871_CR29","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/myc.12836","volume":"61","author":"M Hoenigl","year":"2018","unstructured":"Hoenigl M, et al. Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: new leadership is about working together. Mycoses. 2018;61(11):885\u201394.","journal-title":"Mycoses"},{"issue":"6","key":"871_CR30","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s11046-023-00776-4","volume":"188","author":"M Egger","year":"2023","unstructured":"Egger M, et al. Predictors for Prolonged hospital stay solely to complete intravenous antifungal treatment in patients with candidemia: results from the ECMM candida III multinational european observational cohort study. Mycopathologia. 2023;188(6):983\u201394.","journal-title":"Mycopathologia"},{"issue":"5","key":"871_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jinf.2023.08.001","volume":"87","author":"MC Arendrup","year":"2023","unstructured":"Arendrup MC, et al. European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study. J Infect. 2023;87(5):428\u201337.","journal-title":"J Infect"},{"issue":"9","key":"871_CR32","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1093\/jac\/dkv140","volume":"70","author":"RH Jensen","year":"2015","unstructured":"Jensen RH, et al. Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations. J Antimicrob Chemother. 2015;70(9):2551\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"871_CR33","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1093\/jac\/dkac161","volume":"77","author":"TR Rogers","year":"2022","unstructured":"Rogers TR, et al. Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications. J Antimicrob Chemother. 2022;77(8):2053\u201373.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"871_CR34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.diagmicrobio.2016.02.009","volume":"85","author":"M Castanheira","year":"2016","unstructured":"Castanheira M, et al. Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). Diagn Microbiol Infect Dis. 2016;85(2):200\u20134.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"871_CR35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1128\/JCM.01398-10","volume":"49","author":"MA Pfaller","year":"2011","unstructured":"Pfaller MA, et al. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol. 2011;49(1):396\u20139.","journal-title":"J Clin Microbiol"},{"issue":"6","key":"871_CR36","doi-asserted-by":"publisher","first-page":"R287","DOI":"10.1186\/cc10574","volume":"15","author":"H Muskett","year":"2011","unstructured":"Muskett H, et al. Risk factors for invasive fungal disease in critically ill adult patients: a systematic review. Crit Care. 2011;15(6):R287.","journal-title":"Crit Care"},{"issue":"3","key":"871_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/myc.13211","volume":"64","author":"CL Keighley","year":"2021","unstructured":"Keighley CL, et al. Risk factors for candidaemia: A prospective multi-centre case-control study. Mycoses. 2021;64(3):257\u201363.","journal-title":"Mycoses"},{"issue":"9","key":"871_CR38","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1128\/JCM.00179-11","volume":"49","author":"MC Arendrup","year":"2011","unstructured":"Arendrup MC, et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol. 2011;49(9):3300\u20138.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"871_CR39","doi-asserted-by":"publisher","first-page":"E218","DOI":"10.1111\/1469-0691.12111","volume":"19","author":"J Ericsson","year":"2013","unstructured":"Ericsson J, et al. Candidaemia in Sweden: a nationwide prospective observational survey. Clin Microbiol Infect. 2013;19(4):E218\u201321.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"871_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1128\/JCM.01811-10","volume":"49","author":"MC Arendrup","year":"2011","unstructured":"Arendrup MC, et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol. 2011;49(1):325\u201334.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"871_CR41","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10156-012-0412-9","volume":"18","author":"Y Chong","year":"2012","unstructured":"Chong Y, et al. Fatal candidemia caused by azole-resistant Candida tropicalis in patients with hematological malignancies. J Infect Chemother. 2012;18(5):741\u20136.","journal-title":"J Infect Chemother"},{"issue":"6","key":"871_CR42","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/cid\/ciac004","volume":"75","author":"PB Mazi","year":"2022","unstructured":"Mazi PB, et al. Attributable mortality of candida bloodstream infections in the modern era: a propensity score analysis. Clin Infect Dis. 2022;75(6):1031\u20136.","journal-title":"Clin Infect Dis"},{"key":"871_CR43","doi-asserted-by":"crossref","unstructured":"Salmanton-Garc\u00eda J, Cornely OAC, Stemler J, Barac A, Steinmann J, Siv\u00e1kov\u00e1 A, Akalin EH, Arikan-Akdagli S, Loughlin L, Toscano C, Narayanan M, Rogers B, Willinger B, Akyol D, Roilides E, Lagrou K, Mikulska M, Denis B, Ponscarme D, Scharmann U, Azap A, Lockhart D, Bicanic T, Kron F, Erben N, Rautemaa-Richardson R, Goodman AL, Garcia-Vidal C, Lass-Fl\u00f6rl C, Gangneux J-P, Taramasso L, Ruiz M, Schick Y, Van Wijngaerden E, Milacek C, Giacobbe DR, Logan C, Rooney E, Gori A, Akova M, Bassetti M, Hoenigl M, Koehler P. Attributable mortality of candidemia\u2014results from the ECMM Candida III multinational European Observational Cohort Study. 2024.","DOI":"10.1016\/j.jinf.2024.106229"},{"issue":"1","key":"871_CR44","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S2666-5247(22)00261-0","volume":"4","author":"J Salmanton-Garc\u00eda","year":"2023","unstructured":"Salmanton-Garc\u00eda J, et al. The current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology survey. Lancet Microbe. 2023;4(1):e47\u201356.","journal-title":"Lancet Microbe"},{"key":"871_CR45","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1007\/s11046-024-00831-8","volume":"89","author":"M Hoenigl","year":"2018","unstructured":"Aerts R, et al. Circulatory Inflammatory Proteins as Early Diagnostic Biomarkers for Invasive Aspergillosis in Patients with Hematologic Malignancies-an Exploratory Study. Mycopathol 2024;189(2):24.  https:\/\/doi.org\/10.1007\/s11046-024-00831-8","journal-title":"Mycoses"},{"key":"871_CR46","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1473-3099(20)30784-2","volume":"21","author":"M Hoenigl","year":"2021","unstructured":"Hoenigl M, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis. 2021;21:246\u201357.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"871_CR47","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/13543784.2022.2086120","volume":"31","author":"M Hoenigl","year":"2022","unstructured":"Hoenigl M, et al. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin Investig Drugs. 2022;31(8):795\u2013812.","journal-title":"Expert Opin Investig Drugs"},{"issue":"15","key":"871_CR48","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","volume":"81","author":"M Hoenigl","year":"2021","unstructured":"Hoenigl M, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81(15):1703\u201329.","journal-title":"Drugs"},{"issue":"8","key":"871_CR49","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02345-20","volume":"65","author":"V Duncan","year":"2021","unstructured":"Duncan V, et al. Preliminary characterization of NP339, a novel polyarginine peptide with broad antifungal activity. Antimicrob Agents Chemother. 2021;65(8): e0234520.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"871_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106718","volume":"61","author":"J Salmanton-Garc\u00eda","year":"2023","unstructured":"Salmanton-Garc\u00eda J, et al. The current state of laboratory mycology in Asia\/Pacific: a survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM). Int J Antimicrob Agents. 2023;61(3): 106718.","journal-title":"Int J Antimicrob Agents"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-024-00871-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11046-024-00871-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-024-00871-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T12:17:06Z","timestamp":1724415426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11046-024-00871-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1007\/s11046-024-00871-0","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"11 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LK received research grants from Gilead, and has received honoraria for educational lectures from Gilead, Merck, Sharpe & Dohme, and Vertex Pharmaceuticals outside the submitted work. NG acknowledges support of Wellcome Trust Investigator, Collaborative, Equipment, Strategic and Biomedical Resource awards (101873, 200208, 215599, 224323 and 200208 (the latter awarded to Daan van Aalten)) and the MRC (MR\/M026663\/2) and the MRC Centre for Medical Mycology (MR\/N006364\/2) for support.\u00a0KL received consultancy fees from MRM Health and Mundipharma, speaker fees from Pfizer and Gilead, a service fee from Thermo fisher Scientific and TECOmedical and a fee for Advisory Board participation from MSD and Pfizer, JPG has received lecture honoraria from Gilead, MundiPharma and Pfizer, outside of the submitted work.\u00a0JM reports research grants and\/or personal fees for advisor\/consultant, and\/or speaker\/chairman from Gilead Sciences, F2G, Shionogi, Mundipharma, Mundipharma, Takeda, and Basilea. CLF reports research grants and\/or personal fees for advisor\/consultant, travel and\/or speaker\/chairman from Gilead, MSD, Pfizer, BioM\u00e9rieux, F2G, IMMY, Shionogi, Astellas Pharma. SAA reports research grant from Cidara, lecture honoraria from Gilead, and travel grant from Astellas. M. H. received research funding from Gilead,\u00a0MSD, IMMY, Mundipharma, Scynexis, Melinta, Euroimmune, Shionogi, F2G and Pfizer (all outside of the submitted work). OAC reports grants or contracts from BMBF, Cidara, DZIF, EU-DG RTD, F2G, Gilead, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Abbvie, AiCuris, Basilea, Biocon, Boston Strategic Partners, Cidara, Seqirus, Gilead, GSK, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Mundipharma, Noxxon, Octapharma, Pardes, Partner Therapeutics, Pfizer, PSI, Scynexis, Seres, Shionogi, The Prime Meridian Group; Speaker and lecture honoraria from Abbott, Abbvie, Akademie f\u00fcr Infektionsmedizin, Al-Jazeera Pharmaceuticals\/Hikma, amedes, AstraZeneca, Deutscher \u00c4rzteverlag, Gilead, GSK, Grupo Biotoscana\/United Medical\/Knight, Medscape\/WebMD, MedUpdate, MSD, Moderna, Mundipharma, Noscendo, Paul-Martini-Stiftung, Pfizer, Sandoz, Seqirus, Shionogi, streamedup!, Touch Independent, Vitis; Payment for expert testimony Cidara; Participation on a DRC or DSMB for Cidara, IQVIA, Janssen, MedPace, PSI, Pulmocide. The other authors declare no conflict of interest. SW, SS, JFM no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"70"}}